Post on 12-Jun-2020
transcript
FINAL SCIENTIFICPROGRAMME
AGENDA
8:30 AM 8:45 AM
8:45 AM 9:00 AM
9:00 AM 9:15 AM
9:15 AM 9:30 AM
9:30 AM 9:45 AM
9:45 AM 10:00 AM
10:00 AM 10:40 AM
10:40 AM 11:00 AM
11:00 AM 11:15 AM
11:15 AM 11:40 AM
11:40 AM 12:00 PM
12:00 PM 1:00PM
How I do it Videos: 1. Dissection of right subdiaphragmatic peritoneum & hepatoduodenal ligament2. Mesenteric dissection3. PIPAC4. Dissection around the stomach
Intraperitoneal chemotherapy-types, techniques, tips
Choice of drugs and carriersolutions for intraperitonealchemotherapy
Port directed chemotherapyin peritoneal malignancies
Speaker Chairpersons
PaulSugarbaker
FaheezMohamed
H Ishigami
TSGanesan,SG Ramanan,PrashanthPenumadu
Kalpana B, Pankaj Pandey
Preoperative optimisation ofpatients undergoing CRS/HIPEC
John Bell
Integrating ERAS in a CRS/HIPEC service
Rehabilitation and quality of lifeafter CRS/HIPEC
Optimal management of peritoneal metastasis ingastric cancer
PIPAC-1: Science, indications,technique
Prevention of peritonealmetastasis in gastric cancer
PIPAC-2: safety, efficacy, trials
Tea Break
MartinHubner
Ignace deHingh
MartinHubner
MartinHubner
Ninad K,Ashwin D’Souza
Ayyappan SHemanth Raj
SanjeevDayal
Sanket MehtaMartin HubnerPaulSugarbaker
Day 1
HironoriIshigami
HironoriIshigami
Hemanth Raj E,SM ChandramohanShivendra Singh
Hemanth Raj E,SM ChandramohanShivendra Singh
1:00 PM 2:00 PM
2:00 PM 2:20 PM
2:20 PM 2:45 PM
2:45 PM 3:00 PM
3:00 PM 3:15 PM
3:15 PM 4:00 PM
4:15 PM 5:00 PM
5:00 PM 5:30 PM
5:30PM 6:20 PM
6:20 PM 6:40 PM
6:40 PM 7:00 PM
Current pathological classification of PMP
Management of tumorsof theappendix
Norman Carr
FaheezMohamed
SanjeevDayal
SanjeevDayal
Moderator: Rohin MittalPanelists: Paul SugarbakerNorman Carr, Faheez MohamedAvanish Saklani, Sanket Mehta
Moderator: Sanket Mehta Panelists: Sanjeev Dayal,Hironori Ishigami, HaritChaturvediSVS Deo, Ignace de HinghRobin Thambudorai
Lunch Break
Tea Break
Shirley S,SVS Deo,VikasMahajan
Fertility issues related to thesurgical management ofperitoneal malignancy
What’s new in PMP- smallbowel transplantation
Case discussion: Appendicularmucinous neoplasms
Panel discussion: Challenges instarting a peritonealmalignancy program
Learning curve and minimisingmorbidity in CRS/HIPEC
Shivendra Singh,Ayyappan SSomasekar S P
4:00 PM 4:15 PM
Inauguration and Journal release
Dinner
Training in peritoneal malignancies:Young Indian Perspective
ESPSO fellowship Basingstoke experience ICRETT fellowship Japanese experience
Snita Sinu kumarRohin MittalAshwin RajagopalAruna Prabhu
I de Hingh,AshvinRangole,Sethna K
FaheezMohamed
PaulSugarbaker
F Quenet,Sanket Mehta
HIPEC for rare tumors
7:00 PM 9:00 PM
Day 1
Hall 2- Breakout sessions
1:00 PM 2:00 PM
2:00 PM 2:30 PM
2:30 PM 3:00 PM
3:00 PM 3:20 PM
3:20 PM 3:50 PM
3:50 PM 4:10 PM
4:30 PM 4:50 PM
4:50 PM 5:15 PM
10:00 AM 1:00 PM
Pseudomyxoma peritonei and appendicularneoplasia: a practical approach to histologicaldiagnosisInteractive session with live slide discussionsHighlights:- Recent histological classification of appendicular neoplasia and pseudomyxoma peritonei- Grading of pseudomyxoma peritonei- Differential diagnosis of LAMN
Welcome, preoperative assessment andPrehabilitation
Anaesthetic management of CRS and HIPEC
Anaesthetic implications of chemotherapeuticdrugs used in HIPEC
PIPAC for anaesthesiologists
Post-operative management of theCRS/HIPEC patient
Panel discussion on debatable issuesin peri-op care of CRS-HIPEC
Hemodynamic monitoring and Fluid Management
Lead Faculty: Norman Carr,Shirley S
Kalpana B
John Bell
John Bell
Rakesh Garg
Speaker
Lunch Break
Tea Break
PATHOLOGY
ANAESTHESIOLOGY
Martin Hubner
Sudipta Mukherjee
4:10 PM 4:30 PM
Day 1
Moderator:Meenakshi VV
Nitin BhorkarRajesh HolaluJohn Bell
Tea Break
8:00 AM 9:00 AM
9:00 AM 10:00 AMCase discussion with theexperts - difficult casescenarios
10:00AM 10:20 AM
10:20 AM 10:40 AM OVHIPEC trial results
10:40 AM 11:00 AM
11:00 AM 11:30 AM
Best of India at PSOGI 20181. Failure-to-rescue following CRS and hipec is determined by the type of complication 2. Time to adjuvant chemotherapy & impact on survival in advanced ovarian malignancies3. Extent of peritoneal disease in lower abdomen and it’s relation to nodal disease in stage 3c epithelial ovarian cancer.4. CRS and HIPEC in stage III EOC comparison of oncological outcomes with CRS + IV and CRS+ IP chemotherapy5. Rectal resection does not increase the major morbidity in patients undergoing CRS & hipec for colorectal pm6. Can the negative prognostic impact of a poor/ moderate response to neoadjuvant chemotherapy be offset by a complete interval cytoreductive surgery in patients with advanced epithelial ovarian, fallopian tube and primary peritoneal cancer?
F QuenetRay MD
Ignace de HinghMartin HubnerF QuenetFaheez Mohamed
Amita MaheswariVijaykumar DKGanesan TS
Speaker Chairpersons
TBA
Ignace dehingh
PaulSugarbaker
Rationale and results to datefor treatment of primary &recurrent ovarian cancer
Debate: Extent of peritonectomyfor ovarian cancer
Total parietalAditiBhatt Selective(involved)Vijaykumar DK
Paul Sugarbaker,Hemanth Raj E
Day 2
11:30 AM 12:00 PM
12:00 PM 12:15 PM
12:15 PM 12:30 PM
12:30 PM 1:00 PM
1:00 PM 2:00 PM
2:00 PM 2:30 PM
2:30 PM 2:50 PM
2:50 PM 3:00 PM
3:00 PM 3:15 PM
3:15 PM 3:30 PM
3:30 PM 4:15 PM
4:15 PM 4:30 PM
4:30 PM
How I manage ovarian cancerwith peritoneal metastasis?Initial presentation
Recurrent Ovarian cancer
Is there still a role for portdirected IP chemo in ovariancancer?
Somasekar SP
AbrahamPeedicayil
AmitaMaheswari
Firoz Rajan
Paul Sugarbaker,Hemanth Raj E
EPIC in ovarian cancers
Videos:Pelvic peritonectomyIntraperitoneal port placement
AbrahamPeedicayil,Rejiv RVikas Mahajan
Avanish Saklani,Martin Hubner,Venkatraman R
Aditi BhattSomasekar SP
For-FrancoisQuenetAgainst-Ignace de Hingh
Lunch Break
Debate: Systemic therapy in thecontext of CRS in CRCperitoneal metastasis- forand against
Results of PRODIGE 7 & PROPHYLOCHIP trials
FrancoisQuenet
Ignace deHingh
Paul SugarbakerFaheez Mohamed
Putting PRODIGE-7 inperspective: why thisshould not be the end ofCRS and HIPEC in colorectalperitoneal metastasis
Comments on colorectalHIPEC trials
PaulSugabaker
Open house
Professional collaboration inperitoneal malignancies: - PSOGI- Dutch registry- RENAPE experience- Indian HIPEC registry
Looking through the crystalball-what does the future holdfor peritoneal surfacemalignancies?
Valedictory
Paul SugarbakerI de HinghF QuenetAditi Bhatt
PaulSugarbaker
SVS DeoHemanth Raj E
Day 2
We Thank Our Sponsors
GUFICBIOSCIENCES LIMITED
ThermaSolutions
INSTRUMENT CORPORATION
FRESENIUSKABI
INDIA
THANK YOU...FOR PARTICIPATION